İlker Ertuğrul

İlker Ertuğrul

Auto-generated profile, based on publicly available information

İlker Ertuğrul

Hacettepe University Faculty of Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2014 in Journal of Tropical Pediatrics
Verified
Journal Article
Open access
PDF file
VDVehbi Doğan
Vehbi Doğan
ŞYŞule Yeşil
Şule Yeşil
ŞKŞeyma Kayalı
Şeyma Kayalı
SBSerdar Beken
Serdar Beken
SÖSenem Özgür
Senem Özgür
SKSelmin Karademir
Selmin Karademir
Cardiac rhabdomyoma is the most common primary cardiac tumor, is considered to be a hamartoma of developing cardiac myocytes. Cardiac rhabdomyoma is associated with tuberous sclerosis complex (TSC) in 50–86% of cases. Mutations in TSC-1/TSC-2 genes result in increased mammalian target of rapamycin (mTOR) pathway activation responsible for the hamartomatous lesions of tuberous sclerosis complex. Therapy with mTOR inhibitors is currently under investigation as a treatment option for tumors associated with TSC. In this report we present a case with multiple symptomatic rhabdomyomas associated with tuberous sclerosis complex, deemed to be ineligible for surgical removal, treated with everolimus (mTOR inhibitor). Conclusion: As we observed in our patient, in cases with inoperable symptomatic rhabdomyomas associated with TSC, everolimus, an mTOR inhibitor, may be the treatment of choice, which should be confirmed with additional studies.

3 January 2017 in Echocardiography
Verified
Journal Article
Closed access
MAMehmet Emre Ari
Mehmet Emre Ari
VDVehbi Doğan
Vehbi Doğan
SÖSenem Özgür
Senem Özgür
ÖCÖzben Ceylan
Özben Ceylan
İEİlker Ertuğrul
İlker Ertuğrul
SKSelmin Karademir
Selmin Karademir

13 September 2013 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
IYIşil Yildirim
Işil Yildirim
TKTevfik Karagöz
Tevfik Karagöz
IEİlker Ertuğrul
İlker Ertuğrul
AKAyşe Heves Karagöz
Ayşe Heves Karagöz
SÖSema Özer
Sema Özer

13 December 2017 in Cardiology in the Young
Verified
Journal Article
Closed access
EAEbru Aypar
Ebru Aypar
DADursun Alehan
Dursun Alehan
TKTevfik Karagöz
Tevfik Karagöz
HAHayrettin Hakan Aykan
Hayrettin Hakan Aykan
IEİlKer Ertugrul
İlKer Ertugrul
Background: Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.Aim: Few studies compared the clinical efficacy and safety of switch from bosentan to macitentan only in adult patients with pulmonary arterial hypertension. We aimed to evaluate the clinical efficacy and safety of switch from bosentan to macitentan in children and young adults.Methods: This is a single-institution, 24-week prospective study. Patients ⩾12 years of age with idiopathic/heritable pulmonary arterial hypertension or related to CHD or residual pulmonary arterial hypertension due to repaired congenital systemic-to-pulmonary shunts and on bosentan therapy were included. Concomitant treatment with oral phosphodiesterase type 5 inhibitors and inhaled prostanoids was allowed. Outcome measures included change from baseline to week 24, in the 6-minute walk distance, functional class, oxygen saturation at rest/after 6-minute walk distance test, systolic pulmonary artery pressure estimated by echocardiography, and brain natriuretic peptide levels. Safety end points included adverse events laboratory abnormalities.Results: A total of 13 patients – 5 male and 8 female – completed the study. The mean age was 20.3±6.5 years (12–35) and weight was 54.0±14.5 kg (27–75). Five patients were ⩽18 years of age. Macitentan improved 6-minute walk distance from baseline (mean: 466±35 m (300–590)), at 12 weeks (mean: 494±78 m (325–590), +28 m) (p<0.05), and at 24 weeks (mean: 507±58 m (325–625), +41 m) (p0.05). None of the patients had anaemia, hepatotoxicity, and peripheral oedema.Conclusions: Our study is the first study that showed that switch from bosentan to macitentan significantly improved exercise capacity in children and young adults with pulmonary arterial hypertension and is well tolerated without any adverse events.

30 January 2016 in Iranian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
IEIlker Ertugrul
Ilker Ertugrul
SKSelman Kesici
Selman Kesici
BBBenan Bayrakci
Benan Bayrakci
OUOmer Faruk Unal
Omer Faruk Unal
Background: Tracheostomy was first observed in Egyptian drawings in 3600 BC and performed frequently during the 1800’s diphtheria epidemic. Objectives: The aim of this study was to elucidate the indications, complications, mortality rate, and the effect of pediatric tracheostomy on length of PICU or hospital stay. Materials and Methods: Demographic characteristics, diagnosis at admission, duration of ventilation of 152 patients were analyzed retrospectively. Results: The most common tracheostomy indication was prolonged intubation. The mean duration of mechanical ventilation before tracheostomy was 23.8 days. Forty five percent of the tracheostomy procedures were performed at bedside. Neither the place nor the age had any effect on the development of complications (P = 0.701, P = 0.622). The procedure enabled 62% of the patients to be discharged from hospital. Conclusions: Tracheostomy facilitates discharge and weaning of mechanical ventilation. Although the timing of tracheostomy has to be determined for each individual patient, three weeks of ventilation seems to be a suitable period for tracheostomy. Tracheostomy can be performed at bedside safely but patient selection should be made carefully. Keywords: Pediatric; Intensive Care Unit; Tracheostomy; Complications; Timing

1 December 2021 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
AYAyse Unal Yuksekgonul
Ayse Unal Yuksekgonul
İEİlker Ertuğrul
İlker Ertuğrul
TKTevfik Karagöz
Tevfik Karagöz
"Torsades de pointes", a life-threatening rhythm disorder, is a polymorphic ventricular tachycardia that usually develops in association with a prolonged QT interval. Fluconazole, an anti-fungal drug, may also induce QT prolongation, in some cases subsequent torsades de pointes. Herein, we report a 16-year-old female presenting "torsades de pointes" after administration of fluconazole and rapidly improved upon cessation of the drug.